- Arcutis Biotherapeutics (ARQT, Financial) granted 14,000 restricted stock units to new employees.
- The units have a four-year vesting schedule, with 25% vesting annually.
- This grant is in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement.
Arcutis Biotherapeutics, Inc. (ARQT), a notable player in the immuno-dermatology sector, announced on July 3, 2025, that it has issued a total of 14,000 restricted stock units to two newly hired employees. The Compensation Committee of Arcutis' Board of Directors approved these awards under the 2022 Inducement Plan. This move serves as an inducement to attract top talent, complying with the Nasdaq Listing Rule 5635(c)(4).
The restricted stock units, aimed at incentivizing new hires, will vest over a period of four years. Employees will see 25% of these units vest on each anniversary of the vesting commencement date, contingent on their continuous employment with the company.
Arcutis Biotherapeutics continues to leverage its unique expertise in dermatology to innovate and meet the needs of individuals suffering from inflammatory skin diseases. For more details on their evolving product pipeline and company initiatives, visit their official website at www.arcutis.com.
